Jenburkt Pharmaceuticals Share Price

Jenburkt Pharmaceuticals Limited was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family during the period 1986. The Company engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. It works more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe. The organisation serve to government, semigovernment institutions, missionary hospitals, public sector enterprises, etc. The purpose of the Company is to serve those in need of quality healthcare by bringing revolutionary, lifechanging therapeutic solutions that are accessible to all. Way back in the 20th century, a visionary in the field of healthcare and philanthropic work Shri Nandlal Mulji Bhuta laid the foundation for several groups of companies. Continuing the legacy of Shri Nandlal Mulji Bhuta, his sons Mr. Uttam N. Bhuta and Mr. Hemendra N. Bhuta founded the Company.In 202122, the Company launched a new OTC division Jenburkt Wellness towards better physical and mental health. The first brand launched was Zixa Strong, natural, pain relief product. Further, it launched Nervijen D3 tablets in 202223.Nervijen D3 tablets became the first brand in 2025 to reach a revenue target exceeding during the year. FY 2026 saw genuine distinction while the Company launched Cartisafe Forte, Indias first fixeddose combination of Undenatured Type II Collagen (40 mg), Glucosamine HCl (1500 mg), Chondroitin Sulphate (50 mg), and Hyaluronic Acid (30 mg). It launched Nervijen DP a Pregabalin + Duloxetine combination available in Monthly Compliance Packs (50 mg and 75 mg variants) . Further, it launched Powergesic Natura Oil in association with KLE Ayurvedic Medical College, Belagavi. Additionally, Company launched Powergesic Gel 15 gm, Zixspas, Zixlam Forte, and Piritexyl LD during the year.